Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans
Jianwei Shen(AbbVie (United States)), Volker Fischer(AbbVie (United States)), Kennan C. Marsh(AbbVie (United States)), Aimee Reed(AbbVie (United States)), Olga Kavetskaia(AbbVie (United States)), Rajeev Menon(AbbVie (United States)), Xiaomei Zhang(The University of Texas MD Anderson Cancer Center), Amit Khatri(AbbVie (United States)), Anthony Lee(Pfizer (United States)), Michael D. Serby(AbbVie (United States))
Cited by 19
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
|Nature|2017|853
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|770